General Information of Drug (ID: DM7RYL4)

Drug Name
FG-2216 Drug Info
Indication
Disease Entry ICD 11 Status REF
Kidney disease GC2Z Phase 2 [1]
Cross-matching ID
PubChem CID
6914666
CAS Number
CAS 223387-75-5
TTD Drug ID
DM7RYL4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclopirox DMN5T2A Cutaneous candidiasis 1F23.14 Approved [3]
AKB-6548 DM2EJM3 Anaemia 3A90 Phase 3 [4]
JTZ-951 DM8FSPV Anaemia 3A90 Phase 3 [5]
BAY 853934 DM407I6 Anaemia 3A90 Phase 3 [6]
DS-1093 DM42KZW Anemia 3A00-3A9Z Phase 1 [7]
ZYAN1 DM796RI Anaemia 3A90 Phase 1 [8]
JNJ-42905343 DMCNBHY Anaemia 3A90 Preclinical [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF-prolyl hydroxylase (HPH) TTJQFBG NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018242)
2 Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 DOI: 10.1038/nrd4422
5 DOI: 10.1038/nrneph.2015.82
6 Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
7 Company report (Daiichisankyo)
8 Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
9 Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.